

Piet Dirix MD, PhD



Piet Dirix MD, PhD

PROFESSOR

Oligometastatic cancer: a new disease entity
Radiotherapy for solid tumors
Molecular imagen-guided metastasis directed therapy (MDT) Specialist

Associate Professor at University of Antwerp (Belgium) from August 2014, Associate Professor at KU Leuven (Belgium) from August 2013 and staff member at Iridium Cancer Network (Antwerp, Belgium) from May 2014. He obtained his PhD in medical sciences (KU Leuven, Belgium) and a specialist in radiation oncology (KU Leuven, Belgium). Professor in international ESTRO courses. Editorial board member: Belgian Journal of Medical Oncology (BJMO) and World Journal of Radiology (WJR). Author and co-author of several publications in prestigious journals.

Full name: Piet Dirix

Country: Belgium

Current Position:

2019 – present Staff member at Iridium Cancer Network.

Education:

2012 Specialist in radiation oncology at KU Leuven, Belgium.

2012 Master in hospital management (KU Leuven, Belgium), cum laude.

2010 PhD medical sciences at KU Leuven, Belgium.

2005 Doctor in medicine at KU Leuven, Belgium.

Experience:

2019 – present Staff member at Iridium Cancer Network.

2014 – present Associate Professor at University of Antwerp, Belgium.

2013 - present Associate Professor at KU Leuven, Belgium.

2005 – 2012 Resident in radiation oncology at University Hospitals Leuven, Belgium.

2012 – 2014 Staff member at University Hospitals Leuven, Belgium.

Scientific Publications:

Number of publications as author or co-author: 48

Books: 1

Book chapters: 4

Recent scientific publications:

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P.

A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET).

Mercier C, Dirix P, Ost P, Billiet C, Joye I, Vermeulen P, Lievens Y, Verellen D. BMC Cancer. 2019 Sep 4;19(1):876. doi: 10.1186/s12885-019-6097-z.PMID:31484505

Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial.

Draulans C, Joniau S, Fonteyne V, Delrue L, Decaestecker K, Everaerts W, Dirix P, Van den Bergh L, Crijns W, Vandendriessche H, Van Wynsberge L, Ost P, Lumen N, Buelens P, Haustermans K, Berghen C, De Meerleer G.

JMIR Res Protoc. 2018 Dec 13;7(12):e11256. doi: 10.2196/11256.PMID: 30545809